Who’s showing a clean set of heels at ASCO24?
Who’s getting away from the competition this year?
One of the many challenges in early stage drug development is figuring out who’s showing the competition a clean set of heels…
Meaning to get ahead of the pack.
In the run-up between AACR and ASCO the chatter starts with ‘oh, but the response rate was 66%!’
Only you look at the small print and realise it was 4/6 responders, half of whom were unconfirmed – and may never be confirmed if the tumours have progressed. Ah.
If we look carefully beyond the breathless hype of press releases and curtain raisers, what stands out as trials worth looking at more carefully, for better or worse? Here we offer 15 abstracts to watch out for at ASCO in three weeks time…
To learn more from our latest oncology expert interview and get a heads up on key cancer research insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
This content is restricted to subscribers
